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ABSTRACT 
Metastatic Melanoma has a high mortality rate due to lymphatic progression of the disease.  
Current treatment is surgery followed by radiation and intravenous chemotherapy.  However, 
drawbacks for current chemotherapeutics lie in the fact that they develop resistance and do not 
achieve therapeutic concentrations in the lymphatic system. We hypothesize that a three-drug 
nanoscale drug delivery system, tailored for lymphatic uptake, administered subcutaneously, will 
have decreased drug resistance and therefore offer better therapeutic outcomes.  We prepared and 
characterized nanoparticles (NP) with docetaxel, everolimus, and LY294002 in 
polyethyleneglycol-block-poly(ε-caprolactone) (PEG-PCL) polymer with different charge 
distributions by modifying the ratio of anionic and neutral end groups on the PEG block. These 
NP are similarly sized (~ 48nm), with neutral, partially charged, or fully charged surface. The 
NP are able to load ~ 2mg/mL of each drug and are stable for 24 h.  The NP are assessed for 
safety and efficacy in two transgenic metastatic melanoma mouse models.  All the NP were safe 
in both models based on general appearance, weight changes, death, and blood biochemical 
analyses. The partially charged NP are most effective in decreasing the number of melanocytes 
at both the proximal (sentinel) lymph node (LN) and the distal LN from the injection site. The 
neutral NP are efficacious at the proximal LN, while the fully charged NP have no effect on 
either LN. Thus, our data indicates that the NP surface charge and lymphatic efficacy are closely 
tied to each other and the partially charged NP have the highest potential in treating metastatic 
melanoma.   
 
 
 
GRAPHICAL ABSTRACT 
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INTRODUCTION 
Melanoma is the deadliest form of skin cancer with a very high mortality rate.[1] The standard 
treatment for early stage diagnosis is surgical removal of the tumor and for late stage surgery 
followed by radiation and chemotherapy. Tumor metastasis is the major reason for high mortality 
rates in melanoma. The process begins with the detachment of tumor cells from the adjacent 
endothelial cells and the basement membrane and is accompanied by the secretion of various 
cytokines and growth factors. Migration through the lymphatic vasculature is preferred over 
blood vessels because of reduced flow rates and pressure, easier access to the vessel, and wider 
vessel lumens.[2] Up to 80% of melanomas metastasize  through the lymphatic system.[3] 
Additionally, tumor cells secrete lymphangiogenic growth factors like Vascular Endothelial 
Growth Factors that can stimulate lymphangiogenesis and further promote lymphatic 
migration.[3] These enlarged lymphatic vessels act as a freeway for the metastatic cells to gain 
access and spread to distal lymph nodes (LN) and organs.  
 
Extensive research over the past two decades has helped us elucidate the driver mutations 
occurring in different oncogenes involved in the development of metastatic melanoma. The 
majority studied mutations occur primarily in the BRAF (a serine/threonine protein kinase) genes 
and have approved targeted therapies for patients in stage IV or unresectable melanoma.[4, 5]  
However, newer emerging genetic targets include Neuroblastoma –Rat Sarcoma (NRAS)[4-6] 
and nuclear receptors like Retinoid X Receptor-α (RXRα) genes.[7, 8] In pathological 
conditions, point mutations at the codon 61 of NRAS (NRASQ
61K
) gene locks the activated form 
of NRAS-GTP thereby promoting continuous up regulation of downstream effector proteins and 
signaling pathways in the malignant melanoma phenotype.[9, 10] Activated NRAS
Q61K
 
mutations play a significant role in the development of metastatic melanoma and are the primary 
driver mutations that are responsible for the spread of the disease in humans.[11, 12] These 
oncogenic drivers in the NRAS
 Q61K
 promote invasiveness of the malignant cells and have larger 
nodal involvement when compared to the BRAF mutations.[13] RXRα plays a major role in gene 
expression and signal transduction and in human melanomas the expression of RXRα is lost as 
the disease progresses.[14] Animal studies have indicated that the loss of RXRα in skin 
keratinocytes can lead to the increased melanocyte proliferation and the formation of malignant 
melanomas.[8, 14]  Thus, while therapies targeting the BRAF mutations exist, no such 
therapeutic approaches are currently available for the NRAS or RXR mutations. In the current 
study, we have utilized two melanoma models (1) NRAS
Q61K
 mice with functional RXR and 
activated NRAS in the melanocytes [11], and (2) bigenic NRAS
Q61K
 | RXRαep-/- mice selectively 
lacking RXR in epidermal keratinocytes in combination with the activated NRAS.  Ablation of 
RXRα alongside with NRASQ61K mutations resulted in increased number/size of spontaneous 
melanomas with reduced latency and increased invasion to draining lymph nodes in the 
NRAS
Q61K
 | RXRαep-/- mice.[15]  
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Currently the FDA has 10 approved drugs for the treatment of metastatic melanoma based on 
inhibiting BRAF, mitogen-activated protein kinase, tyrosine kinase, or angiogenesis.[16, 17] The 
major drawback of the current therapy is the inability to deliver therapeutic concentrations to the 
lymphatic system while avoiding systemic toxicity. The majority of these inhibitors are 
administered intravenously (IV), resulting in high doses in the systemic circulation with an 
insufficient dose reaching the lymphatic vasculature. Secondarily, chemoresistance has been 
noted for the approved drugs when used individually.[18] Tumor cells are also known to induce 
resistance by up regulating alternate pathways when one of the pathways is blocked by specific 
inhibitors.[18] Thus, there is a need for a combination therapy that can overcome drug resistance 
by acting on multiple pathways involved in melanoma as well as a drug delivery system that can 
be delivered into the lymphatic system.  
 
Molecules and/or drug delivery systems accumulate in the lymphatics based on molecular 
weight, size, surface charge, and site of administration.[19, 20] A direct correlation between 
lymphatic absorption and molecular weight indicates that molecules with MW > 16,000 Da 
preferentially accumulate into the lymphatics,[21] while, the optimum particle size for lymphatic 
uptake is between 10-80 nm.[22] Anionic charged particles have higher uptake compared to 
cationic or neutral particles, possibly due to the slight negative charge of the interstitium at the 
site of injection.[23] The site of administration also plays a major role in delivering therapeutic 
payloads to the lymphatics where a higher accumulation of injected formulation in lymphatics is 
noted when injected subcutaneously (SC) as compared to the IV.[24]  Any macromolecules or 
nanoscale drug delivery systems injected IV are limited to the vascular space and do not partition 
into the interstitium.  Thus, their uptake into the lymphatics is limited.[22, 25] As most 
chemotherapeutics for the treatment of melanoma are small molecules without the necessary 
properties for lymphatic uptake, a drug delivery system is needed to achieve the necessary 
lymphatic accumulation.  
 
Chemotherapeutics like docetaxel (DTX; PubChem CID: 148124), everolimus (EVR; PubChem 
CID: 6442177), and the experimental compound LY294002 (LY; PubChem CID:  3973) are 
small molecules with MW ranging from 300 to a 1000 Da with low intrinsic aqueous solubilities 
(Figure 2a). Each of these molecules acts on different pathways to inhibit tumor proliferation. 
DTX acts by stabilizing the microtubules, EVR and LY act on mammalian target of rapamycin, 
mTORC1 and mTORC2, respectively.[26-28]   Together, EVR and LY, can completely inhibit 
the mTOR pathway while LY is also capable of inhibiting the Phosphoinositide 3-Kinase (PI3K) 
pathway.[27, 28] However, IV or SC administration of these molecules individually or together 
will lead to systemic absorption with little accumulation in the lymphatic system.  
 
Nanoparticles (NP), prepared with amphiphilic block copolymers, are drug delivery systems that 
can be modified to target the lymphatic system.[29] These block copolymers are comprised of 
hydrophilic and hydrophobic domains with varying chain lengths and different end groups that 
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can be used to modulate NP size and charge density.[30] Additionally, polyester-based polymers 
like polyethylene glycol-block-poly (ε-caprolactone) (PEG-PCL) are biodegradable and 
biocompatible.[30] The NP formulated using these polymers have demonstrated excellent 
stability, increase the drug circulation time, and are capable of solubilizing poorly water soluble 
drugs while simultaneously delivering multiple drugs.[30-32] Incorporation of DTX, EVR, and 
LY into a NP drug delivery system might overcome the chemoresistance issues while 
simultaneously targeting the lymphatics. Therefore, we hypothesize that DTX, EVR, and LY 
loaded PEG-PCL NP with specific size and surface charge density, administered SC, will have 
preferential uptake and accumulation in the lymphatic system and will exert synergistic anti-
proliferative effects in clinically relevant melanoma models. Our objectives are to formulate and 
characterize three-drug loaded NP for the co-delivery of DTX, EVR and LY, and establish to 
their safety and efficacy in relevant melanoma mouse models.  
 
MATERIALS AND METHODS 
Materials 
 
The polymers, methoxy poly(ethylene glycol)-block-poly(ε-caprolactone) (mPEG5000-b-
PCL10000) [Mn=15000; PDI = 1.17] and carboxy poly(ethylene glycol)-block-poly(ε-
caprolactone) COOH-PEG5000-b-PCL10300 [Mn=15300; PDI=1.39] were purchased from 
Advanced Polymer Materials Inc. (Montreal, CAN). DTX, EVR and LY were purchased from 
LC laboratories (Woburn, MA). Slide-A-Lyzer™ Dialysis Cassettes, 20K MWCO were obtained 
from Thermo Scientific Inc (Fairlawn, NJ). A375 human melanoma epithelial cells were 
obtained from American Type Culture Collection (Manassas, VA).  Two metastatic melanoma 
mice models, Tyr NRAS
Q61K 
RXRL2/L2 and Tyr NRASQ61K RXRep-/-, were generated according to 
previous work.[8, 11, 15, 33] CellTiter-Blue
®
 Cell viability Assay was obtained from Promega 
Inc. (Madison, WI). Fontana-Masson stain kit was purchased from American Mastertech 
Scientific, Inc. (Lodi, CA).  All reagents and supplies were purchased from VWR International, 
LLC (Radnor, PA) or Fischer Scientific Inc. (Fairlawn, NJ).  
 
Methods 
Preparation and characterization of three-drug loaded nanoparticles  
 
DTX, EVR and LY three-drug loaded NP were prepared using a solvent evaporation 
method.[34] Briefly, 40 mg of the PEG-PCL polymers at various concentrations were dissolved 
in 2 mL of acetone. For neutral NP only mPEG-PCL (neutral NP) was used, while for partially 
charged NP, a mixture of mPEG: COOHPEG (60:40) (partially charged NP) with PCL was used. 
For the fully charged NP, 100% COOHPEG-PCL (fully charged NP) was used. Stock solutions 
of DTX, EVR and LY in acetone were prepared and required concentrations were added to the 
polymer solution to achieve a final concentration of 2 mg/mL of each drug. The drug polymer 
solution was transferred into a 10 mL round bottom flask and normal saline, 2 mL, was added 
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followed by removal of the organic solvent using a rotary evaporator. The evaporation cycle was 
divided into three segments, with the first segment lasting 7 min at 420 mbar, the second for 7 
min at 320 mbar and the final segment of 6 min at 200 mbar. The temperature of the water bath 
was maintained at 45 
o
C with a rotation of 100 rpm for the round bottom flask. To ensure 
complete removal of acetone the nanoparticle suspension placed in a hood for an additional hour 
to allow for evaporation of any residual acetone.  Under these conditions minimal evaporation of 
normal saline occurs. The final volume was adjusted to 2 mL with saline. The NP were collected 
in a centrifuge tube and spun at 5,000 rpm for 3 minutes and filtered/sterilized using a 0.2 µm 
nylon filter prior to use.  
NP were characterized for size, surface charge distribution, and drug loading. Particle size was 
characterized by Dynamic Light Scattering (DLS) using a Malvern Nano ZS (Malvern 
Instruments Inc, U.K.). All measurements were performed in triplicate and data is presented as 
the mean z-average diameter ± SD (nm) and polydispersity index (PDI ± SD). Statistical analysis 
(one way ANOVA) was performed using Graph Pad Prism software to determine statistical 
significance between the sizes of the empty, partially charged, and fully charged NP. The surface 
charge was measured using the same instrument and the data of three replicates is presented as 
mean zeta potential (ζ) ± SD (mV). The drug loading was determined by reverse phase high 
performance liquid chromatography (RP-HPLC) using a Shimadzu HPLC system consisting of 
LC-20 AT pump and SPD M20 a diode array detector. The analysis was performed using Zorbax 
C8 Column (4.6×75 mm, 3.5 μm) in isocratic mode with acetonitrile/water (62/38) containing 
0.1% phosphoric acid and 1% methanol at a flow rate of 1 mL/min and an injection volume of 10 
μL. Column temperature was maintained at 40 °C. The DTX, LY , and EVR peaks were 
monitored at 227 nm, 303nm and 279 nm respectively at retention times of 1.7, 2.3  and 5.7 min 
respectively. The peak purity for each of the compounds was determined at its respective 
wavelength using the Shimadzu LC Solutions software and based on the peak purity indices for 
all three compounds of 1.000 no impurities for the three peaks were detected (please refer to the 
supplemental information section for a more detailed discussion of the peak purity). The log P 
values for DTX, LY, and EVR are 3.54, 3.33, and 5.9 respectively (Advanced Chemistry 
Development ACD/Universal LogD Module, Percepta 14.0.0 (Build 1996)).  The log D at pH 
7.4 for DTX, LY, and EVR are 3.54, 3.33. and 4.25 (Advanced Chemistry Development 
ACD/Universal LogD Module, Percepta 14.0.0 (Build 1996)). Given the similarity in the log P 
and log D at pH 7.4 for DTX and LY the retention times for both molecules on the RP-HPLC are 
within 0.6 min of each other. All measurements were performed in triplicate and loading data are 
presented as mean drug loading (mg/mL) ± SD. As part of the RP-HPLC quantification residual 
acetone content was also assessed as a quality control measure and residual acetone content in 
the nanoparticles was determined to be 11.2 ± 3.6 mg per day, which is well below the United 
States Pharmacopeia 30 chapter <497> stated limit for a class 3 organic solvent of 50 mg per 
day. 
 
In vitro drug release from the nanoparticles 
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The three-drug NP were prepared as described above. The release profile of DTX, EVR, and LY 
from neutral, partially charged, and fully charged NP was evaluated in 10 mM acetate buffer at 
pH 5.0 and 10 mM phosphate buffer pH 7.4 at 37 °C over 168 h (1 week) under sink conditions 
by dialysis.[35] Briefly, in three separate dialysis cassettes, for each type of NP, 2.0 mL of the 
sample was loaded. A MWCO of 20,000 Da was chosen to enable the unhindered diffusion of 
free drugs along with the unassociated polymer molecules out of the cassette. The cassettes were 
placed in 2.5 L of acetate or phosphate buffer and the temperature was maintained at 37 
o
C for 
the duration of the experiment. Sink conditions were ensured by changing the buffer every 3 h.  
Samples of 20 µL were withdrawn at 0, 0.5, 1, 2, 3, 6, 12, 24, 48, 72, 96, 120, 144, and 168 h and 
were replaced with an equal volume of fresh buffer. Samples were diluted 50 fold in the mobile 
phase and analyzed by RP-HPLC for drug content. The data is presented as mean % drug release 
± SD. Data were curve fitted using a two phase exponential association equation in Graph Pad 
Prism 5 software.  The time required to release 50% of the drug (t1/2) in two phases, fast and 
slow, and the goodness of fit (r
2
) values of three replicates are presented. Statistical Analysis 
using one-way ANOVA with Tukey’s post-test was performed on the release profiles for each 
drug across the different NP to assess for differences in rates of drug release. Statistical analysis 
was performed using GraphPad Prism 5 software. 
 
In vitro cell viability assay and combination index (CI) analysis 
 
A375 human malignant epithelial melanoma cells were seeded at a density of 5,000 cells/well in 
96 well plates and allowed to attach for 12 h at 37 °C.  Post-attachment, cells were treated with 
individual drugs (DTX, EVR, or LY) or two drugs (DTX:EVR, DTX:LY, or EVR:LY) or three 
drugs (DTX:EVR:LY) dissolved in DMSO at equivalent molar ratios. The concentration range 
for all three drugs was between 0.01–10,000 nM. The final concentration of DMSO in the wells 
was 1%. Empty NP and three drug loaded NP cell viability studies were also conducted under 
similar conditions. Cell viability was determined after 72 h by treatment with 20 μL of CellTiter-
Blue
®
 reagent followed by one hour of incubation at 37 °C and fluorescence intensity 
(560EX/590EM) was measured. All measurements were performed in quadruplicate. The mean 
drug concentration at 50% growth inhibition (IC50) was determined using nonlinear fitting using 
a log(inhibitor) vs response – variable slope equation in GraphPad Prism (version 5.00 for 
Windows, GraphPad Software, San Diego California USA).  For combinations in DMSO, the 
concentrations are reported for the most potent drug, usually DTX, except for the EVR:LY 
group, where they are reported in terms of EVR concentration for direct comparison.  The 
combination effect of DTX:EVR, DTX:LY, EVR:LY, and DTX:EVR:LY in DMSO in A375 
cells was evaluated using Compusyn software (Version 1.0, ComboSyn Inc.,U.S.) based on Chou 
and Talalay median-effect principle.[36] Combination Index (CI) values of <1, 1, or > 1 are 
indicative of synergy, additivity, or antagonism respectively.  The software also generates CI 
values at various fractions of cells affected (Fa).  The Fa value is proportional to the dose and 
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therefore Fa vs CI plots can provide the interactive effects of the combinations over the various 
doses tested. The data, in quadruplicate, is presented as Fa vs CI plots to correlate the effect of 
the combinations at different treatment concentrations. CI analysis for NP was not conducted as 
the individual drugs in NP could not be stably produced to directly compare the individual NP 
and the combination NP groups for interactive effects. 
 
In vivo assessment of safety and efficacy in Tyr NRAS
Q61K 
RXRL2/L2and Tyr NRASQ61K RXR ep-/- 
metastatic melanoma mouse models 
 
Tyr NRAS
Q61K 
RXRL2/L2 (RXR+) and Tyr NRASQ61K RXRep-/- (RXR-) metastatic melanoma 
mouse models with the two major mutations (NRAS
Q61k
 and RXRα) found in human melanoma 
were used for the in vivo studies. The generation of Tyr NRAS
Q61K
 mice has been described in 
detail elsewhere.[8, 11, 12, 33] The mice were housed in ventilated cages with free access to 
food and water and were maintained at controlled temperature and humidity conditions for the 
duration of the experiment. Animals that were 8-12 weeks old were sorted into 2 major 
categories (RXR+ or RXR-). In each category, mice were subdivided into 7 groups with 4 
animals per group. The groups included control untreated mice, control empty NP of each charge 
distribution, and treatment drug loaded NP of each charge distribution for a total of 28 animals 
per model (n = 56 for both models). Each group, except the untreated group, was treated with 
empty or three-drug loaded neutral, partially charged, or fully charged NP. Animals were 
injected SC (every week x 3 cycles) proximal to the inguinal (Figure 11) LN with 150 µL/side 
(total volume 300 µL) of the empty or three-drug loaded NP. Based on the drug loading in the 
nanoparticles, the amount of polymer used, and a dose volume of 300 µL per mouse we 
determined the doses for the three drugs in the treatment group.  Thus, each animal received a 
dose of 20 mg/kg of each drug with a total dose of 60 mg/kg for all three drugs in the treatment 
groups and the dose of the polymer was approximately 240 mg/kg for all injected NP.   
During the study (21 days), mice were monitored for signs of acute toxicity such as noticeable 
changes in general appearance, loss in median body weight 15%, or death. On day 21, 7 days 
post last injection, mice were euthanized and blood samples were collected, centrifuged at 3,000 
x g for 7 min and the plasma samples were submitted for complete blood panel chemistry 
analysis. The analysis was performed at Oregon State University Veterinary Diagnostic 
Laboratory. The concentrations of blood urea nitrogen (BUN), creatinine, and alanine 
transaminase (ALT) values were assessed. BUN and creatinine are surrogate markers for kidney 
toxicity while ALT is a  surrogate marker for liver toxicity. [37-39] The quantified values 
between the treatment and the control groups for both models were compared by one-way 
ANOVA with Tukey’s multiple comparison post-test at a p-value of 0.05 using Graph Pad prism 
version 5.00 for Windows to assess organ toxicity. Data are presented as mean parameter value ± 
S.D of four replicates. 
Immediately post-euthanasia and blood collection the inguinal and axillary LN (Figure 1) were 
collected and processed immediately to evaluate the efficacy in terms of reduction in 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
melanocytes in response to the treatment. Briefly, LN were fixed in 4% paraformaldehyde and 
were embedded in paraffin blocks. For histological studies, 5 µm-thick paraffin sections from 
mouse LN were rehydrated and Fontana-Masson (FM) staining was performed according to 
manufacturer’s instructions. FM staining of skin-draining LNs is used as a general label for 
melanin pigment, which represent pigment-producing (melanocytic) cells, the nuclei are stained 
pink using a secondary Nuclear Red dye for contrast.[40] All microscopic studies were 
conducted using Leica DME light microscope and analyzed using Leica Application Suite 
software, version 3.3.1. Images were taken using 20X objective throughout the study. Post 
staining, quantifications of melanin-pigmented area were performed using Adobe Photoshop 
CS5 software. The pictures of LN were analyzed independently in a double-blind manner by two 
investigators, and significance was determined using a student’s two-tailed unpaired t-test as 
calculated by Graph Pad Prism software. Data are presented as mean # of melanocytes/ 
pigmented area ± SD in inguinal or axillary LN for four replicates.  
 
All animal work was conducted in compliance with NIH guideline and Institutional Animal Care 
and Use Committee policy at Oregon State University for End-Stage Illness and Pre-emptive 
Euthanasia based on Humane Endpoints Guidelines. 
 
Figure 1: Phenotypic appearance of Tyr NRAS
Q61K 
RXRL2/L2 (RXR+) or Tyr NRASQ61K RXRep-/- 
(RXR-) with injection site and lymph nodes of interest (Inguinal and Axillary) 
 
RESULTS AND DISCUSSION 
Preparation and characterization of three-drug loaded nanoparticles  
 
Structures for the DTX, EVR, and LY along with a representation of the three-drug loaded NP 
are depicted in Figure 2. DTX, EVR, and LY neutral, partially charged, and fully charged NP are 
formulated by varying ratios of mPEG-PCL and COOH-PEG-PCL. Based on the RP-HPLC data 
the three-drug neutral, partially charged, and fully charged NP are able to solubilize 
approximately 2 mg of each drug and retain each of the drugs at the initial concentrations (within 
6%) for 24 h (Figure 3). The intrinsic aqueous solubilities of DTX, EVR, and LY are 4 
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µg/mL[26], 9.6 µg/mL[27], and 243 µg/mL[28] respectively. Thus, incorporation of these drugs 
into the NP increased the solubility of DTX, EVR, and LY by 455 fold, 201 fold and 8 fold 
respectively, thereby achieving therapeutically relevant dosing concentrations for in vivo 
assessment. Our results are consistent with published results, where the incorporation of 
hydrophobic drugs into amphiphilic diblock copolymers like PEG-PCL increases their aqueous 
solubility and stability.[41, 42]   
 
Figure 2: Structures of DTX, EVR, and LY (a); Schematic representation of the three-drug 
(DTX, EVR and LY) loaded NP (b)  
 
 
Figure 3: Initial loading and drug retention at 24 h for DTX, EVR, and LY in three-drug neutral, 
partially charged, and fully charged NP (Mean ± S.D, n = 3).  The numbers indicate average 
loading concentrations for each individual drug in the NP. 
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The particle sizes and polydispersity index (PDI) for the three-drug neutral, partially charged, 
and fully charged NP are presented in Table 1. The neutral, partially charged, and fully charged 
NP show unimodal distribution as indicated with PDI values of less than 0.35. After 24 h under 
refrigeration and at room temperature, the size was re-assessed and no changes are seen in size or 
distribution (data not shown). No changes in the size over time are indicative of stability as no 
aggregation of the NP is occurring. Statistical analysis of the size distribution indicates that there 
is no significant difference between the particle sizes for neutral, partially charged, and fully 
charged NP. The mean zeta potential for neutral, partially charged, and fully charged NP are also 
presented in Table 1. As anticipated, the magnitude of the charge distribution correlates well 
with the increasing percentage of the negatively charged COOH-PEG-PCL content in the NP.  
 
Size and surface charge are critical parameters in the selective uptake of NP into the lymphatic 
system.[20] PEG-PCL diblock copolymers can produce NP of uniform size (around 50 nm) that 
can selectively pass through the gaps in lymphatic endothelium (30-100 nm).[43] Additionally, 
studies have shown that particles with a size above 20 nm accumulate into the lymphatics, 
however, when the particle size exceeds 100 nm the rate of particle drainage from the interstitum 
slows significantly.[20]  Thus, optimal particle sizes for interstitial drainage and lymphatic 
accumulation are between 10 – 80 nm.[2] Accordingly, the drug loaded PEG-PCL NP in our 
study with an average size of 48 nm are expected to preferentially accumulate into the 
lymphatics.  Surface charge is the other key parameter for lymphatic accumulation.[44] It has 
been widely reported in the literature that anionic NP have a higher uptake into lymphatic vessels 
when compared to their neutral and cationic counterparts.[2] Other studies have indicated that 
highly negative charged particles can trigger macrophage uptake.[45] Therefore, we anticipate 
that based on the surface charge distribution a differential accumulation of the NP in the lymph 
nodes in vivo will occur. Additionally, as all of the NP have similar sizes any differences in 
lymphatic uptake can be attributed to the difference in surface charge alone.  
 
    Mean Size  SD (nm) PDI  SD 
Mean Zeta Potential (ζ)  SD 
(mV) 
Neutral NP 48.08  0.31 0.31  0.01 -6.4  0.24 
Partially charged NP 48.30  0.42 0.25  0.01 -19.2  2.15 
Fully charged NP 48.60  0.66 0.31  0.02 -37.6  1.02 
Table 1: Particle Size, PDI, and Zeta potential values for three-drug neutral, partially charged 
and fully charged NP (Mean ± SD, n = 3) 
 
In vitro drug release from the nanoparticles 
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The release profiles of DTX, EVR and LY from the three-drug neutral, partially charged, and 
fully charged NP at pH 5.0 and 7.4 are shown in Figure 4 and the final % drug released values 
are presented in Table 2 ..  
Drug 
% Drug Released at 168 h 
Neutral NP Partially Charged NP Fully Charged NP 
pH 5.0 pH 7.4 pH 5.0 pH 7.4 pH 5.0 pH 7.4 
DTX 72.00 ± 2.16 72.42 ± 2.66 68.55 ± 0.43 75.01 ± 1.78 69.80 ± 1.07 73.60 ± 1.82 
EVR 44.58 ± 1.61 51.67 ± 5.83 46.23 ± 0.85 58.23 ± 2.18 48.19 ± 2.85 61.38 ± 4.67 
LY 81.18 ± 1.22 81.60 ± 1.39 80.12 ± 1.42 81.90 ± 0.67 80.33 ± 0.52 81.24 ± 2.07 
Table 2: The % drug released values for DTX, EVR, and LY in neutral, partially charged, and 
fully charged NP at pH 5.0 and 7.4 over 168 h.  Data presented is Mean ± SD (n = 3) 
 
The highest % release occurred with LY, followed by DTX, and then EVR. Overall, there is no 
significant difference in the rates of drug release for each drug from NP of different 
compositions at the same pH (Table 2 and Figure 4). The release profile of DTX, EVR and LY 
from the neutral, partially charged, and fully charged NP was almost identical at both pHs and 
exhibited no statistically significant difference (Table 2).  The two phase exponential association 
t1/2 and r
2
 values for DTX, EVR, and LY release from the neutral, partially, and fully charged NP 
are presented in Table 3. However, the fast an slow half-lives were longer at pH 7.4 as compared 
to pH 5 as expected due to the higher rate of ester hydrolysis of the PEG-PCL at the lower pH.  
As seen in Figure 4, there is an initial phase involving burst/rapid release of the drugs from the 
NP followed by a more sustained release pattern at later stages. This biphasic release pattern 
exhibited by PEG-PCL NP has been well documented in the literature.[46, 47] The initial burst 
release is primarily driven by the desorption and the diffusion of surface adsorbed drug particles, 
while the secondary phase of drug release is driven by the erosion of the NP matrix and drug 
diffusion processes. The inner segment, PCL, is a biodegradable polyester that has a high 
crystallinity while the outer PEG shell increases the porosity in the PCL matrix and thereby 
allows the diffusion of drugs from the matrix into the buffer.[48] Thus drug release is governed 
by diffusion of the drug and erosion/degradation of the NP matrix.[49]  Previous studies have 
demonstrated that solid state interactions between the drug and the hydrophobic block, and the 
mobility of the hydrophobic block all govern the drug release rate.[46] LY has the fastest drug 
release from the three-drug NP followed by DTX and then EVR. This may be due to the relative 
hydrophobicities of these molecules and their potential interaction with the PCL domain. The log 
D values at pH 7.4 for LY, DTX and EVR are 3.33, 3.54, and 4.25 respectively (Advanced 
Chemistry Development ACD/Universal LogD Module, Percepta 14.0.0 (Build 1996)). 
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Figure 4: In vitro drug release profiles of DTX  at pH 7.4 (a) and pH 5.0 (b), EVR at pH 7.4 (c) 
and pH 5.0 (d), and LY at pH 7.4 (e) and pH 5.0 (f) from neutral, partially charged, and fully 
charged NP under sink conditions over 48 h.(Mean % drug release ± S.D, n = 3) 
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NP Drug 
pH 5.0 pH 7.4 
Fast 
t1/2 (h) 
Slow t1/2 
(h) 
r
2
 
Fast t1/2 
(h) 
Slow t1/2 
(h) 
r
2
 
Neutral NP 
DTX 0.42 19.49 0.9924 2.05 23.93 0.9817 
EVR 0.23 28.25 0.9822 0.61 63.20 0.9099 
LY 0.31 5.93 0.9902 0.83 13.72 0.9957 
Partially charged 
NP 
DTX 0.42 22.75 0.9865 2.46 26.84 0.9816 
EVR 0.21 31.17 0.9644 0.51 59.53 0.9843 
LY 0.33 5.93 0.9803 0.50 12.83 0.9964 
Fully charged 
NP 
DTX 0.53 23.73 0.9936 2.10 25.90 0.9600 
EVR 0.39 27.03 0.9717 0.45 56.38 0.9226 
LY 0.38 5.44 0.9945 0.70 11.41 0.9955 
 
Table 3: Fast and slow half-lives (t1/2) and goodness of fit (r
2
) values of DTX, EVR, and LY in 
neutral, partially charged, and fully charged NP at pH 5.0 and 7.4 using a two phase association 
curve fitting.  
 
In vitro cell viability assay and combination index (CI) analysis 
 
The anti-proliferative effects (IC50 values) of DTX, EVR, and LY in DMSO individually and in 
two- and three-drug combinations evaluated in A375 human melanoma cells are presented in 
Figure 5(a). The two-drug combinations and the three-drug combinations in DMSO exhibited 
strong inhibition of A375 cell proliferation over a wide range of tested doses. Based on the data 
(Figure 5(a)) the two- and three- drug combinations are more potent as compared to the 
individual drug treatments, with the three-drug combination demonstrating the highest potency at 
0.57 nM concentration. The two- and three- drug combinations were also evaluated for 
interactive effects (synergistic, additive, or antagonistic) using Compusyn software and the data 
are presented in Figure 5(b). The two-drug combination EVR:LY is synergistic at lower 
concentrations but becomes additive at higher concentrations. The DTX:EVR and DTX:LY 
combinations are synergistic at all concentrations (Figure 5(b)). The three-drug combination is 
also synergistic at all the fractions affected indicating that the multiple mechanisms of action 
enhance the potency of the combination beyond what is expected with individual drug treatments 
alone. The combination neutral, partially charged, and fully charged NP were also evaluated for 
their respective IC50 values and data is presented in Figure 5(c).  Not surprisingly the NP have a 
higher IC50 values as compared to the drugs/combinations in DMSO.  This is due to the fact that 
the drug must not undergo diffusion from the NP and release is also dependent on the 
degradation of the NP. Additionally, the cell culture conditions do not mimic the sink conditions 
one can expect in vivo further slowing down the rate of drug release from the NP.  Our findings 
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are consistent with other published studies documenting the same phenomena.[50, 51]  The 
empty NP did not affect cell viability (data not shown).  CI analysis for NP was not feasible as 
the individual drugs in NP could not be stably produced to directly compare the individual NP 
and the combination NP groups for interactive effects. 
 
The two-drug combinations, DTX:EVR and DTX:LY, illustrate the need to target multiple 
pathways, such as microtubule stabilization and mTOR inhibition.  Interestingly, with EVR:LY, 
which specifically targets mTOR1 and mTOR2, at higher concentrations A357 cells seem to be 
able to overcome the synergy of this one pathway and maybe up/down regulating others and 
becoming less susceptible to drug(s) effects.  Not surprisingly, the three-drug combination 
achieves sustained synergistic effects at the highest potency by blocking multiple pathways 
involved in cancer progression. Cancer cells up regulate alternative mechanisms to induce drug 
resistance when one particular pathway is blocked.[52] The mTOR pathway is involved in cell 
growth, proliferation, and survival, and in addition it affects downstream effector proteins which 
are essential for the protein translation processes.[52] It has been reported previously that the 
mTOR pathway is highly up regulated in malignant melanoma due to the NRAS mutation [53] 
and inhibiting the mTOR pathway can have beneficial effects in the treatment regimen.[54] EVR 
acts on the mTOR1 pathway and it is known that the cancer cells immediately up regulate the 
mTOR2 pathway to induce drug resistance when the mTOR1 pathway is blocked.[55] LY targets 
the mTOR2 pathway and also blocks the PI3K/AKT pathway. Thus, when LY is used in 
combination with EVR, the mTOR cascade is completely blocked.[54] Ablation of RXRα 
alongside with NRAS
Q61K
 mutations results in an increased number/size of spontaneous 
melanomas with reduced latency and increased invasion to draining lymph nodes in the 
NRAS
Q61K
 | RXRαep-/- mice).[15]  Thus, far there are no drugs targeting this mutation 
specifically.  Therefore, the three drug combination was evaluated in both the RXR+ and RXR- 
mice to determine the efficacy of the regimen in both. DTX acts by a completely different 
mechanism where it  stabilizes the microtubules and thereby induces apoptosis as a general 
chemotherapeutic strategy.[56] Thus, the combination of these three drugs can synergistically 
inhibit proliferation through multiple mechanisms of action as evidenced by the potency and CI 
for the three-drug combination as compared to individual drugs or the two-drug combinations.  
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Figure 5: Mean IC50 values of DTX, EVR, LY, two- and three-drug combinations in DMSO in 
A375 metastatic melanoma cells (n = 4) (a). Fa vs CI plot of the two- and three- drug 
combinations in A375 metastatic melanoma cells (n = 4) (b). Mean IC50 values of three-drug 
combination neutral, partially charged and fully charged nanoparticles in A375 metastatic 
melanoma cells (n = 4) (c) 
 
In vivo assessment of safety and efficacy in Tyr NRAS
Q61K 
RXRL2/L2and Tyr NRASQ61K RXR ep-
/-
 metastatic melanoma mouse models 
 
The safety profile of the neutral, partially charged, and fully charged NP has been evaluated in 
two metastatic melanoma mouse models containing activating NRAS
Q61K
 driver mutation and 
with or without RXR protein (RXR+ or RXR-), which develop melanoma with different 
latency and with LN metastasis as described elsewhere.[15] None of the mice in either model 
died or exhibited abnormal behavioral changes during the duration of the study. Changes in the 
weight, during the course of the study, for the neutral, partially charged, and fully charged NP, 
with or without the three drugs are presented in Figure 6. Based on the data, none of the groups 
in either model demonstrated weight loss  15% indicating that neither the empty NP nor the 
three-drug NPs produce acute toxicity at 20 mg/kg dose of each drug (total 60 mg/kg dose) and 
240 mg/kg of the NP polymer. 
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Figure 6: Normalized body weight of mice injected subcutaneously with empty or three drug NP 
in Tyr Nras
Q61K 
RXRL2/L2 (RXR+) (a, c, and e) and Tyr NrasQ61K RXRep-/- (RXR-) (b, d, and f) 
mice. Neutral NP in RXR+ (a) and RXR- (b), partially charged NP in RXR+ (c) and RXR- (d) 
mice, and fully charged NP in RXR+ (e) and RXR- (f) mice. The mice were injected at a dose of 
20 mg/kg for each drug in the treatment group and 240 mg/kg of the polymer in all groups.  The 
arrows indicate the days of injection (0, 7, 14). The dashed line depicts the threshold weight loss 
of 15% which is indicative of acute toxicity. (Mean normalized weight % ± S.D, n=4). 
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The blood biochemical values for BUN, Creatinine, and ALT, for all the groups in each model 
are presented in Figures 7 – 9.  BUN, Creatinine, and ALT values in RXR+ and RXR- treated 
with empty neutral or three-drug neutral NP indicates that there are no statistically significant 
differences between the treatment groups and the untreated and vehicle controls (Figure 7).  
Similar results were seen with the partially charged (Figure 8) and fully charged (Figure 9) NP 
groups. BUN, and creatinine levels are indicators of kidney function.[38] In cases of renal 
toxicity, levels of BUN and/or creatinine are elevated.[38] ALT is present in all tissues 
throughout the entire body, but is particularly concentrated in liver, bile duct, kidney, and 
bone.[39] Elevated ALT levels are usually indicative of liver toxicity.[39]   Based on the 
behavioral observations, weight data (Figure 5), and the biochemical estimations (Figure 7 – 9) 
no acute toxicity is observed with either the empty or three-drug loaded NP.   
 
 
Figure 7: Blood panel data from mice injected subcutaneously with vehicle (empty neutral NP) 
or treatment (three-drug neutral NP) in Tyr NRASs
Q61K 
RXRL2/L2 (RXR+) and Tyr NRASQ61K 
RXRep-/- (RXR-) mice.  BUN (a), Creatinine (b), and ALT (c). Mean parameter value ± S.D, 
n=4.  One way ANOVA with Tukey’s Multiple Comparison test was used for statistical analysis 
at p-value of 0.05 
 
 
Figure 8: Blood panel data from mice injected subcutaneously with vehicle (empty partially 
charged NP) or treatment (three-drug partially charged NP) in Tyr NRAS
Q61K 
RXRL2/L2 (RXR+) 
and Tyr NRAS
Q61K 
RXRep-/- (RXR-) mice. BUN (a), Creatinine (b), and ALT (c). Mean 
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parameter value ± S.D, n=4. One way ANOVA with Tukey’s Multiple Comparison test was used 
for statistical analysis at p-value of 0.05 
 
Figure 9: Blood panel data from mice injected subcutaneously with vehicle (empty fully charged 
NP) or treatment (three-drug fully charged NP) in Tyr NRAS
Q61K 
RXRL2/L2 (RXR+) and Tyr 
NRAS
Q61K 
RXRep-/- (RXR-) mice. BUN (a), Creatinine (b), and ALT (c). Mean parameter value 
± S.D, n=4. One way ANOVA with Tukey’s Multiple Comparison test was used for statistical 
analysis at p-value of 0.05 
The effectiveness of the treatment in the two different models of metastatic melanoma mouse 
models is established using Fontana Masson (FM) staining of the LN followed by quantification 
of pigment areas covered with invading melanocytes in the draining LN using Adobe Photoshop 
CS5 software. The melanocyte covered pigmented area (black stain) between the empty NP and 
the three-drug NP for the same charge distribution were compared to quantify the efficacy, in 
terms of decrease in the number of  invasive, malignant melanocytes in the LNs.   
A representative microscopic data set from the inguinal and axillary LN is presented in Figure 9 
for RXR+ and RXR- mice treated with neutral, partially charged, and fully charged empty or 
three-drug NP. The reduction in the transformed melanocytes covered pigmented area is 
dependent on the uptake and trafficking of the differently charged NP in the lymphatic system. 
As seen in figure 10(a), with three-drug neutral NP as compared to empty neutral NP a reduction 
in melanocytes area in the inguinal LN (proximal to the injection sites) is seen in both models 
(RXR+ and RXR-), however, no change in pigmented melanocytes area was noted in the axillary 
LN (distal from the injection sites). Thus, indicating that the efficacy of the drug loaded neutral 
particles is limited to the inguinal LN in both models. Analysis of melanocyte covered 
pigmented area indicates a statistically significant difference (p = 0.0003) at the inguinal LN of 
both the RXR+ and RXR- groups (Figure 11 (a & b)), but no difference is observed at the 
axillary LN. One possible explanation is that the NP remained at the site of injection after dosing 
and showed efficacy only at the proximal inguinal LN. One of the ways by which particles traffic 
into the lymphatic system is through charge repulsion between the NP and the interstitium at the 
site of injection.[44] For the neutral NP the magnitude of the surface charge may not be large 
enough to induce electrostatic repulsions to allow for distal trafficking through the lymphatics. 
Additionally, studies by others have shown that neutral NP tend to aggregate at the site of 
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injection which may also confirm our findings that the particles do not track distally into the 
lymphatics but show efficacy regionally.[57]  
 
In comparing the three-drug partially charged NP to empty partially charged NP (Figure 10(b)), a 
decrease in melanocytes at both the inguinal and the axillary LN in both models is noted. These 
results indicate that the three-drug partially charged NP are efficacious at both the proximal 
(inguinal) and distal (axillary) LN as referenced from the site of injection for both the models.  
Analysis of melanocyte covered pigmented area indicates a statistically significant difference at 
both the inguinal (p < 0.0001) and the axillary (p < 0.0001) LN in both the mouse models upon 
treatment with the three-drug partially charged NP (Figure 11(c & d)). The lymphatic vessels and 
the interstitium have a slight negative charge because of the presence of glycosaminoglycans and 
the electrostatic repulsions between these and the partially charged NP (surface charge of -19 
mV) may be responsible for the deeper movement of the particles into the lymphatic system.[44] 
The ability of these NP to track into the distal LN may provide an excellent opportunity to target 
advanced stages of metastatic melanoma and improve patient outcomes. 
 
Comparing the staining in empty fully charged and three-drug fully charged NP (Figure 10(c)), 
no difference at either the inguinal or the axillary LN is observed in both models. Thus, 
establishing that the fully charged NP did not have appreciable accumulation in either of the two 
LN studied. Analysis of melanocyte covered pigmented area indicates no difference between 
empty and three-drug fully charged NP at both the inguinal and axillary LN in both models 
(Figure 11(e & f)). The data indicates that highly negatively charged particles did not tract into 
either the regional or distal LN (Figure 10c, 11e & f).  Previously published literature has 
suggested that highly negatively charged particles are rapidly taken up and sequestered by 
macrophages.[45] The high anionic charge on these NP also tends to attract serum proteins 
resulting in the formation of a protein corona that promotes the release of signals for macrophage 
uptake.[45]  For example, anionic polystyrene nanoparticles have 4 times higher uptake by 
macrophages in serum as compared to uptake from buffer solutions indicting the role of serum 
proteins in the uptake mechanism and kinetics.[45] Research has also indicated that highly 
anionic nanoparticles resemble bacteria in their surface charge and therefore interact 
preferentially with phagocytic cells.[58] Additional studies in the future to characterize the 
immune responses triggered by the different NPs may shed light about the involvement of 
immune cells, including the macrophages, in the lymphatic tracking of these NP.   
  
We have used two different animal models in this study containing mutations in NRAS and/or 
RXR to elucidate the effectiveness of our developed drug delivery system and to characterize 
the efficacy and toxicity of our formulated NP.[4-8, 11]  The Tyr NRAS
Q61K
RXRL2/L2 (RXR+) 
mice represent a model with increased latency to develop invasive melanoma while Tyr 
NRAS
Q61K
RXRep-/- (RXR-) bigenic mice, selectively lacking RXR in the epidermis alongside 
with the activating NRAS mutation in the melanocytes, represent a metastatic melanoma model 
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where melanoma cells readily migrate and invade the lymphatics.[9, 33]Analysis of melanocyte 
covered pigmented area comparing RXR+ and RXR- for the three-drug NP with same charge 
distribution indicates that no statistically significant difference is demonstrated (Figures 10 & 
11).  Thereby indicating that the NP retained efficacy across the two different melanoma models. 
Future studies using fluorescent dye loaded NP will be performed to obtain further insight about 
the biodistribution of these NP while simultaneously tracking their lymphatic movement and 
accumulation. 
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Figure 10: Representative pictures of FM staining of LN sections after treatment with  vehicle 
(empty NP) or treatment (three-drug NP) in Tyr NRAS
Q61K 
RXRL2/L2 (RXR+) and Tyr NRASQ61K  
RXRep-/- (RXR-) mice.  Neutral NP in RXR+ and RXR- mice (a), partially charged NP in RXR+ 
and RXR- mice (b), and fully charged NP in RXR+ and RXR- mice (c) .The mice were injected 
at a dose of 20 mg/kg for each drug in the treatment group and 240 mg/kg of the polymer in all 
groups on days 0, 7, and 14. Scale bar: 100 µm (n = 4) 
 
 
 
Figure 11: Mean melanocytic pigmented area per field (µm
2
) treated with empty or three-drug 
NP in Tyr NRAS
Q61K 
RXRL2/L2 (RXR+) and Tyr NRASQ61K RXRep-/- (RXR-) negative mice.  
Neutral NP in RXR+ (a) and RXR- (b) mice, partially charged NP in RXR+(c) and RXR- (d) 
mice, fully charged NP in RXR+ (e) and RXR- (f) mice. The mice were injected at a dose of 20 
mg/kg for each drug in the treatment group and 240 mg/kg of the polymer in all groups on days 
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0, 7, and 14. Values are expressed as a mean ± SEM (n =4). *indicates statistical significance as 
determined by a Student’s two-tailed unpaired t-test with a p-value of 0.05 
 
CONCLUSION 
In summary, we have developed and characterized a three-drug (DTX, EVR and LY) NP that 
acts synergistically in vivo in two different melanoma mouse models.  Our results indicate that 
the effect of the three-drug neutral NP is proximal to the site of injection, while the three-drug 
partially charged NP track further into the lymphatic system reaching more distal LNs. In 
contrast, the three-drug fully charged NP have minimal effects on the proximal or distal LN. The 
three-drug combination neutral and partially charged NP are highly effective in treating 
melanoma in both models and provide the basis for a novel therapeutic option treating metastatic 
melanoma that is targeted to the site of action, i.e. the lymphatic system.   
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